Articles
Pharma news highlights: Gleevec, pay-to-delay, human gene patents and data analysis errors

Pharma news highlights: Gleevec, pay-to-delay, human gene pa...

This month, Ed Silverman discusses the issues within the pharma industry around pay-to-delay, the Gleevec decision, human gene patenting and data analysis errors for Diovan. Various legal matters have dominated headlines since our last appearance here. The most prominent, of course, involved a…

Articles
chris-helfrich

Spotlight on... malaria

Our latest ‘spotlight on’ coincides with our April focus on infectious diseases, taking a look into the causes, symptoms and treatments of malaria. It is hard to imagine that a single mosquito bite could end your life. But for thousands of people in the...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D